177Lu-NM600靶向放射性核素治疗延长三阴性乳腺癌同系小鼠模型的生存期
本研究在三阴性乳腺癌(TNBC)同系小鼠模型中,用86Y-NM600进行PET显像评估肿瘤靶向与剂量学,并用177Lu-NM600开展靶向放射性核素治疗。结果显示肿瘤靶向良好、正常组织清除快,治疗耐受良好并显著抑制肿瘤生长、延长总生存,60%的4T07荷瘤小鼠达完全缓解。作者认为177Lu-NM600对TNBC具有潜力,值得在临床环境中进一步探索。
要点
- 86Y-NM600 PET在4T07和4T1模型中显示良好肿瘤靶向与快速正常组织清除。
- 177Lu-NM600对4T07和4T1肿瘤的吸收剂量分别为2.04±0.32和1.68±0.06 Gy/MBq,高于肝脏和骨髓。
- 9.25或18.5 MBq的177Lu-NM600耐受良好,显著抑制肿瘤生长并延长总生存。
核心结论
- 作者认为177Lu-NM600靶向放射性核素治疗对TNBC具有潜力,值得在临床环境中进一步探索。
研究设计与样本
- 研究在雌性BALB/C小鼠的同系4T07(非转移性)和4T1(转移性)TNBC移植瘤模型中进行。
- 86Y-NM600用于PET显像(每组n=3-5),177Lu-NM600用于靶向放射性核素治疗。
- 毒性评估在未荷瘤BALB/C小鼠中给予9.25或18.5 MBq的177Lu-NM600,观察体重、全血细胞计数和组织病理学。
- 荷4T07或4T1移植瘤的小鼠(n=5-6)接受赋形剂或9.25或18.5 MBq的177Lu-NM600单次或分次方案,监测肿瘤生长和总生存。
主要发现
- 86Y-NM600在4T07和4T1两种模型中均显示良好肿瘤靶向和快速正常组织清除。
- 离体生物分布证实了PET数据的准确性,并验证86Y-NM600可作为177Lu-NM600的替代示踪剂。
- 177Lu-NM600剂量学显示4T07和4T1肿瘤的吸收剂量分别为2.04±0.32和1.68±0.06 Gy/MBq,高于肝脏的1.28±0.09 Gy/MBq和骨髓的0.31±0.05 Gy/MBq。
- 治疗所用177Lu-NM600注射活度耐受良好,在两种TNBC模型中均产生显著肿瘤生长抑制并延长总生存。
- 60%的4T07荷瘤治疗小鼠达到完全缓解。
关键数值与推荐
- 177Lu-NM600治疗活度为9.25或18.5 MBq,可单次或分次给药。
- 4T07肿瘤吸收剂量2.04±0.32 Gy/MBq,4T1肿瘤1.68±0.06 Gy/MBq,肝脏1.28±0.09 Gy/MBq,骨髓0.31±0.05 Gy/MBq。
- 4T07荷瘤小鼠完全缓解率为60%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is a clinically unmet need for effective treatments for triple-negative breast cancer (TNBC), as it remains the most aggressive subtype of breast cancer. Herein, we demonstrate a promising strategy using a tumor-targeting alkylphosphocholine (NM600) for targeted radionuclide therapy of TNBC. Methods: NM600 was radiolabeled with 86Y for PET imaging and 177Lu for targeted radionuclide therapy. 86Y-NM600 PET imaging was performed on female BALB/C mice bearing syngeneic 4T07 (nonmetastatic) and 4T1 (metastatic) TNBC tumor grafts (n = 3-5). Quantitative data derived from a PET-image region-of-interest analysis, which was corroborated by ex vivo biodistribution, were used to estimate the dosimetry of 177Lu-NM600 treatments. Weight measurement, complete blood counts, and histopathology analysis were performed to determine 177Lu-NM600 toxicity in naïve BALB/C mice administered 9.25 or 18.5 MBq. Groups of mice bearing 4T07 or 4T1 grafts (n = 5-6) received excipient or 9.25 or 18.5 MBq of 177Lu-NM600 as a single or fractionated schedule, and tumor growth and overall survival were monitored. Results: Excellent tumor targeting and rapid normal-tissue clearance of 86Y-NM600 were noted in both 4T07 and 4T1 murine models. Ex vivo biodistribution corroborated the accuracy of the PET data and validated 86Y-NM600 as a surrogate for 177Lu-NM600. 177Lu-NM600 dosimetry showed absorbed doses of 2.04 ± 0.32 and 1.68 ± 0.06 Gy/MBq to 4T07 and 4T1 tumors, respectively, which were larger than those delivered to liver (1.28 ± 0.09 Gy/MBq) and to bone marrow (0.31 ± 0.05 Gy/MBq). The 177Lu-NM600 injected activities used for treatment were well tolerated and resulted in significant tumor growth inhibition and prolonged overall survival in both tested TNBC models. A complete response was attained in 60% of treated mice bearing 4T07 grafts. Conclusion: Overall, our results suggest that 177Lu-NM600 targeted radionuclide therapy has potential for TNBC and merits further exploration in a clinical setting.
引用
- Hernandez R, Grudzinski JJ, Aluicio-Sarduy E, et al. 177Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer. J Nucl Med. 2019. PMID: 31862799. doi:10.2967/jnumed.119.236265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。